We’re creating a diverse and balanced pipeline and platform to complement our poly (ADP-ribose) polymerase (PARP) inhibitor, niraparib, and our investigational PD-1 inhibitor, dostarlimab (TSR-042, anti-PD-1), across tumor types and targets. These combinations were carefully selected to inform individual tumor strategies in areas of unmet need, involving novel combinations with different mechanisms of action. Our pipeline approach is guided by applying science for patients first, all with the goal of bringing potentially transformative therapies to people living with cancer.
a: PARP Inhibitor
b: anti-PD-1 mAb
c: anti-TIM-3 mAb
d: anti-LAG-3 mAb
*In collaboration with the European Network for Gynaecological Oncological Trial groups (ENGOT). Bevacizumab may be included as part of the chemotherapy and maintenance regimen per local standard of care.
BRCA, breast cancer susceptibility gene; HER, human epidermal growth factor receptor; mAb, monoclonal antibody; PARP, poly ADP ribose polymerase.